Intervention not reported
Bifocal spectacles vs SVLs with timolol drops · children with myopia (nearsightedness)
1 finding from 1 review
- no estimate extracted1 study · 97 participantsModerate
Findings
What do systematic reviews say?
57 questions · 58 findings · 4 reviews · Eyes and Vision
No studies found 14 · 24.1%GRADE not reported 1 · 1.7%Very low 5 · 8.6%Low 15 · 25.9%Moderate 21 · 36.2%High 2 · 3.4%
Intervention not reported
Tropicamide plus bifocal spectacles vs SVLs · children with myopia (nearsightedness)
1 finding from 1 review
- no estimate extracted1 study · 50 participantsGRADE not reported
Intervention not reported
Comparison (intervention vs comparator) · children with myopia (nearsightedness)
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Intervention not reported
Adverse effects · children with myopia (nearsightedness)
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Intervention not reported
Multifocal vs single vision lens spectacles · children with myopia (nearsightedness)
1 finding from 1 review
- no estimate extracted9 studies · 1463 participantsModerate
Intervention not reported
Peripheral plus spectacles vs single vision lens spectacles · children with myopia (nearsightedness)
1 finding from 1 review
- no estimate extracted3 studies · 597 participantsLow
Intervention not reported
Bifocal vs single vision soft contact lenses · children with myopia (nearsightedness)
1 finding from 1 review
- no estimate extracted4 studies · 300 participantsLow
Intervention not reported
Rigid gas permeable contact lenses vs spectacles or soft contact lenses · children with myopia (nearsightedness)
1 finding from 1 review
- no estimate extracted2 studies · 420 participantsVery low
Intervention not reported
Orthokeratology contact lenses vs single vision lenses · children with myopia (nearsightedness)
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Intervention not reported
Spherical aberration soft contact lenses vs single vision soft contact lenses · children with myopia (nearsightedness)
1 finding from 1 review
- no estimate extracted2 studies · 209 participantsLow
Intervention not reported
Antimuscarinic agents vs placebo · children with myopia (nearsightedness)
1 finding from 1 review
- no estimate extracted3 studies · 629 participantsModerate
Intervention not reported
Atropine vs tropicamide · children with myopia (nearsightedness)
1 finding from 1 review
- no estimate extracted1 study · 196 participantsLow
Omega‐3 vs placebo
Change in visual loss associated with PSR: visual loss is defined by the deterioration of visual acuity of 3 lines or more with the Snellen chart · people with AMD
Omega 3 fatty acids probably leads to higher loss of 3 or more lines of VA at 24 months compared with placebo (moderate certainty).
2 findings from 1 review
- Omega 3 fatty acids for preventing or slowing the progression of age‐related macular degeneration 2015 · Cochrane Headline outcomes onlyRR 1.141 study · 236 participantsModerate
- Omega 3 fatty acids for preventing or slowing the progression of age‐related macular degeneration 2015 · Cochrane Headline outcomes onlyRR 1.251 study · 230 participantsModerate
Omega‐3 vs placebo
Incidence of CNV at 24 months · people with AMD
Omega 3 fatty acids probably leads to higher incidence of CNV at 24 months compared with placebo (moderate certainty).
1 finding from 1 review
- Omega 3 fatty acids for preventing or slowing the progression of age‐related macular degeneration 2015 · Cochrane Headline outcomes onlyRR 1.061 study · 224 participantsModerate
Omega‐3 vs placebo
Incidence of CNV at 36 months · people with AMD
Omega 3 fatty acids probably leads to higher incidence of CNV at 36 months compared with placebo (moderate certainty).
1 finding from 1 review
- Omega 3 fatty acids for preventing or slowing the progression of age‐related macular degeneration 2015 · Cochrane Headline outcomes onlyRR 1.121 study · 195 participantsModerate
Omega‐3 vs placebo
Progression of AMD (dichotomous) · people with AMD
Omega 3 fatty acids showed no clear difference in progression of AMD over 5 years compared with placebo (high certainty).
1 finding from 1 review
- Omega 3 fatty acids for preventing or slowing the progression of age‐related macular degeneration 2015 · Cochrane Headline outcomes onlyHR 0.96 [0.84, 1.1]2 studies · 2343 participantsHigh
Omega‐3 vs placebo
Adverse effects · people with AMD
Omega 3 fatty acids leads to higher adverse effects compared with placebo (high certainty).
1 finding from 1 review
- Omega 3 fatty acids for preventing or slowing the progression of age‐related macular degeneration 2015 · Cochrane Headline outcomes onlyRR 1.012 studies · 2343 participantsHigh